Work

A phase II study of mammalian target of rapamycin (mTOR) inhibitor RAD001 plus imatinib mesylate (IM) in patients with previously treated advanced renal carcinoma (RCC)

Year: 2007

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2007.25.18_suppl.15600

Authors: J. S. Chan, J. Vuky, L. A. Besaw, T. M. Beer, C. W. Ryan

Institutions: Virginia Mason Medical Center, Oregon Health & Science University

Language: English

Topic: Renal cell carcinoma treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2286186015

Cites:

Cited by: 6

Related to: 10